儿童非结核分枝杆菌病研究进展

doi:10.3969/j.issn.2096-8493.2021.02.017

摘要/Abstract

摘要：

非结核分枝杆菌(non-tuberculous mycobacteria,NTM)是分枝杆菌属内除结核分枝杆菌复合群(Mycobacterium tuberculosis complex,MTBC)和麻风分枝杆菌以外的其他分枝杆菌。NTM种类繁多,不同菌种对药物的敏感性和耐药性差异较大,临床和病理表现多不典型,常导致儿童NTM病误诊和漏诊。为进一步加深对儿童NTM病的认识,提高临床诊治水平,笔者结合近年来国内外儿童NTM病的文献和研究成果,从NTM分类、流行病学特征、致病机制、诊断和治疗等方面展开综述。

关键词: 分枝杆菌感染,非典型性, 儿童, 诊断,鉴别, 治疗结果, 综述文献(主题)

Abstract:

Non-tuberculous mycobacteria (NTM) belong to Mycobacterium except for Mycobacterium tuberculosis complex (MTBC) and Mycobacterium leprae. Owing to the various kinds of NTMs and the varied drug sensitivity and resistance, clinical and pathological manifestations are atypical, which often lead to misdiagnosis and missed diagnosis of NTM disease in children. To have a comprehensive understanding of NTM disease and to improve the clinical diagnosis and treatment, this article reviews the NTM in classification, epidemiological characteristics, pathogenic mechanism, diagnosis and treatment based on the recent research.

Key words: Mycobacterium infections, atypical, Children, Diagnosis, differential, Treatment outcome, Review literature as topic

郭倩, 申晨. 儿童非结核分枝杆菌病研究进展[J]. 结核与肺部疾病杂志, 2021, 2(2): 184-188. doi: 10.3969/j.issn.2096-8493.2021.02.017

GUO Qian, SHEN Chen. The progress of non-tuberculous mycobacterium disease in children[J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 184-188. doi: 10.3969/j.issn.2096-8493.2021.02.017

参考文献 46

[1]	Dolezalova K, Maly M, Wallenfels J, et al. Nontuberculous mycobacterial infections in children in the Czech Republic in the period 2003—2018. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2020. Doi: 10.5507/bp.2020.025. doi: 10.5507/bp.2020.025
[2]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020,43(11):918-946. Doi: 10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[3]	Jeon D. Infection Source and Epidemiology of Nontuberculous Mycobacterial Lung Disease. Tuberc Respir Dis (Seoul), 2019,82(2):94-101. Doi: 10.4046/trd.2018.0026. doi: 10.4046/trd.2018.0026 URL
[4]	Tebruegge M, Pantazidou A, MacGregor D, et al. Nontuberculous Mycobacterial Disease in Children-Epidemiology, Diagnosis & Management at a Tertiary Center. PloS One, 2016,11(1):e147513. Doi: 10.1371/journal.pone.0147513. doi: 10.1371/journal.pone.0147513
[5]	Pham-Huy A, Robinson JL, Tapiéro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health, 2010,15(5):276-282. Doi: 10.1093/pch/15.5.276. doi: 10.1093/pch/15.5.276 URL
[6]	Remus N, Reichenbach J, Picard C, et al. Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood. Pediatr Res, 2001,50(1):8-13. Doi: 10.1203/00006450-200107000-00005. doi: 10.1203/00006450-200107000-00005 pmid: 11420412
[7]	Zimmermann P, Curtis N, Tebruegge M. Nontuberculous mycobacterial disease in childhood-update on diagnostic approaches and treatment. J Infect, 2017,74 Supp l1:S136-S142. Doi: 10.1016/S0163-4453(17)30204-9. doi: 10.1016/S0163-4453(17)30204-9 URL
[8]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020,56(1):2000535. Doi: 10.1183/13993003.00535-2020. doi: 10.1183/13993003.00535-2020 URL
[9]	Lee H, Myung W, Koh WJ, et al. Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007—2016. Emerg Infect Dis, 2019,25(3):569-572. Doi: 10.3201/eid2503.181597. doi: 10.3201/eid2503.181597 URL
[10]	Yu X, Liu P, Liu G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect, 2016,73(6):558-567. Doi: 10.1016/j.jinf.2016.08.020. doi: 10.1016/j.jinf.2016.08.020 URL
[11]	Kontturi A, Soini H, Ollgren J, et al. Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guerin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016. Clin Infect Dis, 2018,67(8):1256-1261. Doi: 10.1093/cid/ciy241. doi: 10.1093/cid/ciy241 URL
[12]	Aung TT, Yam JK, Lin S, et al. Biofilms of Pathogenic Nontuberculous Mycobacteria Targeted by New Therapeutic Approaches. Antimicrob Agents Chemother, 2016,60(1):24-35. Doi: 10.1128/AAC.01509-15. doi: 10.1128/AAC.01509-15 URL
[13]	Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet, 2013,381(9877):1551-1560. Doi: 10.1016/S0140-6736(13)60632-7. doi: 10.1016/S0140-6736(13)60632-7 URL
[14]	Hoiby N, Bjarnsholt T, Moser C, et al. Diagnosis of biofilm infections in cystic fibrosis patients. APMIS, 2017,125(4):339-343. Doi: 10.1111/apm.12689. doi: 10.1111/apm.12689 URL
[15]	Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016,71(Suppl 1):i1-i22. Doi: 10.1136/thoraxjnl-2015-207360. doi: 10.1136/thoraxjnl-2015-207360 URL
[16]	El Helou G, Viola GM, Hachem R, et al. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis, 2013,13(2):166-174. Doi: 10.1016/S1473-3099(12)70316-X. doi: 10.1016/S1473-3099(12)70316-X URL
[17]	陈晓文, 吴利先. 非结核分枝杆菌的毒力因子及免疫机制研究进展. 中国病原生物学杂志, 2020,15(5):609-611. Doi: 10.13350/j.cjpb.200524. doi: 10.13350/j.cjpb.200524
[18]	马莹聪. TLR2及TLR4在巨噬细胞识别非结核分枝杆菌中的作用研究. 吉林农业大学, 2015.
[19]	Wang X, Chen S, Ren H, et al. HMGN2 regulates non-tuberculous mycobacteria survival via modulation of M1 macrophage polarization. J Cell Mol Med, 2019,23(12):7985-7998. Doi: 10.1111/jcmm.14599. doi: 10.1111/jcmm.14599 URL
[20]	Barry AO, Mege JL, Ghigo E. Hijacked phagosomes and leukocyte activation: an intimate relationship. J Leukoc Biol, 2011,89(3):373-382. Doi: 10.1189/jlb.0510270. doi: 10.1189/jlb.0510270 URL
[21]	Zimmermann P, Tebruegge M, Curtis N, et al. The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis. J Infect, 2015,71(1):9-18. Doi: 10.1016/j.jinf.2015.02.010. doi: 10.1016/j.jinf.2015.02.010 URL
[22]	López-Varela E, García-Basteiro AL, Santiago B, et al. Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis. Lancet Respir Med, 2015,3(3):244-256. Doi: 10.1016/S2213-2600(15)00062-4. doi: 10.1016/S2213-2600(15)00062-4 pmid: 25773213
[23]	Penn R, Steehler MK, Sokohl A, et al. Nontuberculous mycobacterial cervicofacial lymphadenitis-a review and proposed classification system. Int J Pediatr Otorhinolaryngol, 2011,75(12):1599-1603. Doi: 10.1016/j.ijporl.2011.09.018. doi: 10.1016/j.ijporl.2011.09.018 URL
[24]	Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014,59(2):147-159. Doi: 10.1093/cid/ciu296. doi: 10.1093/cid/ciu296 URL
[25]	Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis, 2009,15(9):1351-1358, 1544. Doi: 10.3201/eid1509.081259. doi: 10.3201/eid1509.081259 URL
[26]	Haimi-Cohen Y, Amir J, Eidlitz-Markus T, et al. Chronic cheek lesions: an unusual manifestation of nontuberculous mycobacterial cevicofacial infection. J Pediatr, 2009,155(5):746-748, e1. Doi: 10.1016/j.jpeds.2009.03.031. doi: 10.1016/j.jpeds.2009.03.031 URL
[27]	Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros, 2016,15(3):380-385. Doi: 10.1016/j.jcf.2015.09.007. doi: 10.1016/j.jcf.2015.09.007 URL
[28]	Lu M, Saddi V, Britton PN, et al. Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis. Paediatr Respir Rev, 2019,29:42-52. Doi: 10.1016/j.prrv.2018.05.001. doi: 10.1016/j.prrv.2018.05.001
[29]	Gardner AI, McClenaghan E, Saint G, et al. Epidemiology of Nontuberculous Mycobacteria Infection in Children and Young People With Cystic Fibrosis: Analysis of UK Cystic Fibrosis Registry. Clin Infect Dis, 2019,68(5):731-737. Doi: 10.1093/cid/ciy531. doi: 10.1093/cid/ciy531
[30]	Bhattacharya J, Mohandas S, Goldman DL. Nontuberculous Mycobacterial Infections in Children. Pediatr Rev, 2019,40(4):179-190. Doi: 10.1542/pir.2018-0131. doi: 10.1542/pir.2018-0131 pmid: 30936399
[31]	Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med, 2015,36(1):91-99. Doi: 10.1016/j.ccm.2014.11.002. doi: 10.1016/j.ccm.2014.11.002 URL
[32]	Esther CJ, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros, 2010,9(2):117-123. Doi: 10.1016/j.jcf.2009.12.001. doi: 10.1016/j.jcf.2009.12.001 URL
[33]	符彬莎, 黄梅会, 王旭明. 儿童偶发分枝杆菌脓毒症1例报告. 临床儿科杂志, 2020,38(5):374-376. Doi: 10.3969/j.issn.1000-3606.2020.05.015. doi: 10.3969/j.issn.1000-3606.2020.05.015
[34]	Kurashima A. Japanese new guidelines for nontuberculous mycobacterial pulmonary disease. Kekkaku, 2010,85(2):87-93.
[35]	Cruz AT, Mph MD. Nontuberculous mycobacterial skin and soft tissue infections in children[EB/OL]. [2019-11-16]. https://www.uptodate.com/contents/nontuberculous-mycobacterial-skin-and-soft-tissue-infections-in-children/print.
[36]	Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis, 2016,45:123-134. Doi: 10.1016/j.ijid.2016.03.006. doi: 10.1016/j.ijid.2016.03.006
[37]	Preece CL, Perry A, Gray B, et al. A novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fibrosis. J Cyst Fibros, 2016,15(2):186-191. Doi: 10.1016/j.jcf.2015.05.002. doi: 10.1016/j.jcf.2015.05.002 URL
[38]	Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007,175(4):367-416. Doi: 10.1164/rccm.200604-571. doi: 10.1164/rccm.200604-571 URL
[39]	Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis, 2007,44(8):1057-1064. Doi: 10.1086/512675. doi: 10.1086/512675 URL
[40]	Harb JL, Pascal E, Compton RA, et al. What is the optimal management of pediatric nontuberculous mycobacterial cervicofacial lymphadenitis? Laryngoscope, 2020,130(6):1359-1361. Doi: 10.1002/lary.28459. doi: 10.1002/lary.28459 URL
[41]	Mahadevan M, Neeff M, Van Der Meer G, et al. Non-tuberculous mycobacterial head and neck infections in children: Analysis of results and complications for various treatment modalities. Int J Pediatr Otorhinolaryngol, 2016,82:102-106. Doi: 10.1016/j.ijporl.2015.12.026. doi: 10.1016/j.ijporl.2015.12.026 URL
[42]	Ng SS, Tay YK, Koh MJ, et al. Pediatric Cutaneous Nontuberculous Mycobacterium Infections in Singapore. Pediatr Dermatol, 2015,32(4):488-494. Doi: 10.1111/pde.12575. doi: 10.1111/pde.12575 URL
[43]	Palenque E. Skin disease and nontuberculous atypical mycobacteria. Int J Dermatol, 2000,39(9):659-666. Doi: 10.1046/j.1365-4362.2000.00821.x. doi: 10.1046/j.1365-4362.2000.00821.x pmid: 11044189
[44]	陈品儒, 谭守勇. 外科手术在非结核分枝杆菌肺病治疗中的作用探讨. 中国防痨杂志, 2020,42(2):159-163. Doi: 10.3969/j.issn.1000-6621.2020.02.014. doi: 10.3969/j.issn.1000-6621.2020.02.014
[45]	Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis, 1999,28(5):1080-1085. Doi: 10.1086/514748. doi: 10.1086/514748 pmid: 10452638
[46]	Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med, 2006,173(11):1283-1289. Doi: 10.1164/rccm.200509-1531OC. doi: 10.1164/rccm.200509-1531OC URL